Aclaris Therapeutics Inc. (ACRS)
NASDAQ: ACRS
· Real-Time Price · USD
1.47
-0.06 (-3.92%)
At close: Jun 13, 2025, 3:59 PM
1.44
-2.11%
After-hours: Jun 13, 2025, 05:43 PM EDT
Aclaris Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Contract research Revenue | 2.54M | 3.04M | 4.39M | 5.83M |
| Contract research Revenue Growth | -16.28% | -30.94% | -24.61% | n/a |
| License and Service Revenue | 16.18M | 28.21M | 25.1M | n/a |
| License and Service Revenue Growth | -42.66% | +12.41% | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 6.14M | 4.95M | 5.65M | 4.65M | 4.34M | 8.21M | 7.09M | 8.32M | 8.79M | 7.15M | 5.81M | 6.08M | 6.1M | 6.94M | 5.98M | 5.87M | 4.83M | 4.9M | 3.86M | 5.57M | 6.2M | 5.81M | 6.29M | 15.17M | 18.02M | 19.66M | 17.95M | 18.99M | 17.49M | 12.5M | 8.12M | 7.33M | 5.16M | 4.68M | 3.65M | 3.15M | 3.6M | 2.4M | 1.23M | 803K | 892K |
| Selling, General, and Administrative Revenue Growth | +23.92% | -12.37% | +21.52% | +7.09% | -47.11% | +15.84% | -14.74% | -5.38% | +23.01% | +22.93% | -4.31% | -0.39% | -12.16% | +16.12% | +1.86% | +21.61% | -1.45% | +26.92% | -30.74% | -10.13% | +6.73% | -7.59% | -58.55% | -15.84% | -8.34% | +9.51% | -5.45% | +8.55% | +39.97% | +53.86% | +10.82% | +42.11% | +10.12% | +28.33% | +15.76% | -12.51% | +50.17% | +94.81% | +53.42% | -9.98% | n/a |
| Research and Development Revenue | 11.58M | 9.03M | 5.96M | 8.76M | 9.85M | 26.65M | 23.88M | 25.27M | 22.59M | 21.07M | 23.66M | 18.78M | 14.31M | 14.1M | 13.98M | 7.9M | 7.84M | 8.96M | 6.87M | 6.47M | 9.44M | 11.54M | 16.18M | 17.62M | 19.92M | 19.54M | 15.93M | 13.98M | 13.61M | 13.19M | 10.86M | 7.96M | 7.77M | 6.94M | 7.16M | 9.84M | 9.54M | 2.4M | 9.41M | 1.79M | 1.74M |
| Research and Development Revenue Growth | +28.34% | +51.54% | -32.00% | -11.03% | -63.05% | +11.60% | -5.54% | +11.90% | +7.19% | -10.92% | +25.97% | +31.27% | +1.45% | +0.90% | +76.98% | +0.75% | -12.48% | +30.44% | +6.19% | -31.53% | -18.16% | -28.69% | -8.17% | -11.53% | +1.96% | +22.64% | +13.92% | +2.78% | +3.16% | +21.40% | +36.40% | +2.48% | +11.94% | -3.06% | -27.19% | +3.16% | +296.96% | -74.47% | +424.71% | +3.22% | n/a |